Susquehanna International Group’s Cartesian Therapeutics RNAC Stock Holding History

Susquehanna International Group’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,300	Closed	-$125K	–	13970
2025 Q4	$125K	Buy	17,300 +700	+4%	+$5.66K	﹤0.01%	11322
2025 Q3	$170K	Buy	+16,600	New	+$187K	﹤0.01%	11154
2022 Q4	–	Sell	-653	Closed	-$32K	–	13490
2022 Q3	$32K	Buy	653 +150	+30%	+$8.24K	﹤0.01%	12425
2022 Q2	$20K	Buy	503 +40	+9%	+$1.19K	﹤0.01%	12366
2022 Q1	$17K	Sell	463 -10	-2%	-$626	﹤0.01%	12669
2021 Q4	$46K	Sell	473 -70	-13%	-$7.53K	﹤0.01%	12593
2021 Q3	$68K	Sell	543 -414	-43%	-$50K	﹤0.01%	12239
2021 Q2	$120K	Sell	957 -4,053	-81%	-$483K	﹤0.01%	11991
2021 Q1	$680K	Buy	5,010 +3,980	+386%	+$494K	﹤0.01%	8747
2020 Q4	$94K	Buy	1,030 +363	+54%	+$31.5K	﹤0.01%	10522
2020 Q3	$50K	Buy	+667	New	+$51.1K	﹤0.01%	10199

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's RNAC Position: Q4 2025 in Review

Susquehanna International Group sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 12,330 shares — an estimated $99.7K sold.

Susquehanna International Group first reported a position in RNAC in Q1 2017 and held it in 21 quarters. The position peaked at $1.17M in Q1 2023. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

Susquehanna International Group reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
Susquehanna International Group sold 12,330 Cartesian Therapeutics shares in Q4 2025, an estimated $99.7K.
Susquehanna International Group first reported a position in Cartesian Therapeutics in Q1 2017 and held it in 21 quarters.
Susquehanna International Group's Cartesian Therapeutics position peaked at $1.17M in Q1 2023.
67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.